Trastuzumab can prolong the survival time of breast cancer patients, but the research on the effect of anti-HER2 therapy on cognitive function is very rare and controversial, and the findings on the correlation between HER2 status and cognitive deficits are full of contradictions. Here, ERBB2 is linked to breast cancer.